Combination of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 are biomarkers for the detection of colon tubular adenocarcinoma

Table 1 Serum levels of pro-gastrin-releasing peptide and neutrophil gelatinase-associated lipocalin in tubular adenocarcinoma patients

Case	Gender	Age	Pathologic grade	pro-GRP (pg/mL)	Relative NGAL expression
Normal	M	64	Polyps	12.32 ± 0.30	1 ± 0.02
P1	M	76	Mild tubular adenocarcinoma	50.02 ± 0.80	10.62 ± 0.10
P2	F	78	Mild tubular adenocarcinoma	58.86 ± 1.31	19.90 ± 0.22
P3	F	45	Mild tubular adenocarcinoma	50.99 ± 0.85	12.17 ± 0.15
P4	M	74	Mild tubular adenocarcinoma	55.71 ± 1.15	17.14 ± 0.20
P5	M	65	Mild tubular adenocarcinoma	65.87 ± 2.61	22.56 ± 0.27
P6	F	80	Mild tubular adenocarcinoma	52.52 ± 1.01	15.34 ± 0.19

M: Male; F: Female; NGAL: Neutrophil gelatinase-associated lipocalin pro-GRP: Pro-gastrin-releasing peptide.

Table 2 Serum levels of pro-gastrin-releasing peptide, neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 in different patient groups

Group	Case	Gender	Age	Pathologic grade	pro-GRP (pg/mL)	Relative NGAL expression	Relative MMP-9 expression
Normal	N-1	M	64	--	11.51 ± 0.31	1.00 ± 0.02	1.00 ± 0.01
Normal	N-2	M	62	--	6.33 ± 0.13	0.81 ± 0.01	0.98 ± 0.01
Normal	N-3	M	59	--	8.54 ± 0.12	0.93 ± 0.03	0.94 ± 0.02
Normal	N-4	M	67	--	15.67 ± 0.37	1.03 ± 0.02	0.97 ± 0.01
Normal	N-5	M	48	--	8.34 ± 0.21	1.12 ± 0.03	1.02 ± 0.02
Normal	N-6	M	52	--	13.51 ± 0.33	0.96 ± 0.01	1.04 ± 0.02
Normal	N-7	M	69	--	16.62 ± 0.41	0.89 ± 0.01	1.00 ± 0.01
Normal	N-8	M	56	--	6.88 ± 0.22	1.08 ± 0.04	2.03 ± 0.03
Normal	N-9	M	70	--	17.36 ± 0.31	0.97 ± 0.03	0.96 ± 0.01
Normal	N-10	M	65	--	18.24 ± 0.35	1.21 ± 0.03	1.06 ± 0.02
I	I-1	M	54	Polyps	15.68 ± 0.27	1.31 ± 0.02	1.02 ± 0.01
I	I-2	F	65	Polyps	17.83 ± 0.31	1.42 ± 0.04	1.08 ± 0.02
I	I-3	F	66	Polyps	20.12 ± 0.35	1.90 ± 0.04	1.28 ± 0.03
I	I-4	M	74	Polyps	24.38 ± 0.46	2.84 ± 0.06	4.32 ± 0.12
I	I-5	M	65	Polyps	29.67 ± 0.36	3.85 ± 0.07	2.35 ± 0.06
I	I-6	F	71	Polyps	62.56 ± 0.83	4.24 ± 0.10	2.76 ± 0.07
I	I-7	F	55	Polyps	38.94 ± 0.46	2.09 ± 0.06	3.00 ± 0.06
I	I-8	M	62	Polyps	40.54 ± 0.52	5.56 ± 0.12	5.12 ± 0.13
I	I-9	M	64	Polyps	43.86 ± 0.49	7.21 ± 0.16	3.44 ± 0.09
I	I-10	M	68	Polyps	60.91 ± 0.75	8.23 ± 0.20	3.71 ± 0.11
II	II-1	M	68	Mild tubular adenocarcinoma	55.32 ± 0.46	3.97 ± 0.12	4.06 ± 0.12
II	II-2	M	72	Mild tubular adenocarcinoma	30.13 ± 0.36	13.81 ± 0.23	4.53 ± 0.18
II	II-3	F	65	Mild tubular adenocarcinoma	52.54 ± 0.53	15.06 ± 0.25	4.89 ± 0.20
II	II-4	F	70	Mild tubular adenocarcinoma	58.25 ± 0.49	5.68 ± 0.18	4.07 ± 0.17
II	II-5	M	75	Mild tubular adenocarcinoma	35.02 ± 0.56	18.37 ± 0.29	4.61 ± 0.22
II	II-6	M	77	Mild tubular adenocarcinoma	61.45 ± 0.67	21.35 ± 0.35	2.92 ± 0.15
II	II-7	M	65	Mild tubular adenocarcinoma	62.38 ± 0.74	23.69 ± 0.37	4.82 ± 0.27
II	II-8	F	63	Mild tubular adenocarcinoma	64.43 ± 0.48	24.92 ± 0.24	4.85 ± 0.26
II	II-9	M	57	Mild tubular adenocarcinoma	68.67 ± 0.46	26.74 ± 0.30	5.68 ± 0.22
II	II-10	M	62	Mild tubular adenocarcinoma	70.5 ± 0.71	28.32 ± 0.32	6.04 ± 0.17
III	III-1	M	67	Severe tubular adenocarcinoma	72.53 ± 0.83	31.03 ± 0.26	6.36 ± 0.22
III	III-2	M	65	Severe tubular adenocarcinoma	76.27 ± 0.96	37.17 ± 0.32	6.47 ± 0.20
III	III-3	F	80	Severe tubular adenocarcinoma	79.81 ± 1.13	38.44 ± 0.41	7.53 ± 0.31
III	III-4	F	76	Severe tubular adenocarcinoma	84.56 ± 1.41	43.68 ± 0.50	8.68 ± 0.25
III	III-5	M	65	Severe tubular adenocarcinoma	86.01 ± 1.06	45.79 ± 0.55	4.70 ± 0.19
III	III-6	F	71	Severe tubular adenocarcinoma	90.12 ± 1.28	49.31 ± 0.61	9.05 ± 0.35
III	III-7	M	66	Severe tubular adenocarcinoma	93.17 ± 1.33	53.81 ± 0.53	9.52 ± 0.28
III	III-8	M	78	Severe tubular adenocarcinoma	94.24 ± 1.57	54.68 ± 0.62	9.35 ± 0.34
III	III-9	F	67	Severe tubular adenocarcinoma	93.08 ± 1.82	65.76 ± 0.72	9.41 ± 0.27
III	III-10	F	72	Severe tubular adenocarcinoma	107.38 ± 2.34	85.91 ± 0.96	14.84 ± 0.38

M: Male; F: Female; NGAL: Neutrophil gelatinase-associated lipocalin pro-GRP: Pro-gastrin-releasing peptide; MMP-9: Matrix metalloproteinase-9.